Commonwealth Equity Services LLC Has $312.53 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by on May 10th, 2023

Commonwealth Equity Services LLC boosted its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,769,186 shares of the company’s stock after buying an additional 26,167 shares during the quarter. Johnson & Johnson makes up about 0.8% of Commonwealth Equity Services LLC’s holdings, making the stock its 17th biggest position. Commonwealth Equity Services LLC owned about 0.07% of Johnson & Johnson worth $312,526,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Glassy Mountain Advisors Inc. bought a new position in shares of Johnson & Johnson during the 4th quarter worth about $35,000. Retirement Financial Solutions LLC bought a new position in Johnson & Johnson during the 4th quarter valued at about $40,000. TD Capital Management LLC bought a new position in Johnson & Johnson during the 3rd quarter valued at about $48,000. VitalStone Financial LLC bought a new position in Johnson & Johnson during the 4th quarter valued at about $52,000. Finally, Iron Horse Wealth Management LLC lifted its holdings in Johnson & Johnson by 112.8% during the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after purchasing an additional 159 shares during the last quarter. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $161.05 on Wednesday. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49. The firm’s fifty day moving average price is $158.62 and its two-hundred day moving average price is $166.91. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $183.35. The firm has a market capitalization of $418.53 billion, a P/E ratio of 33.69, a price-to-earnings-growth ratio of 2.78 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The firm had revenue of $24.75 billion for the quarter, compared to the consensus estimate of $23.61 billion. During the same period in the previous year, the company earned $2.67 earnings per share. The company’s quarterly revenue was up 5.6% on a year-over-year basis. As a group, research analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be issued a $1.19 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a dividend yield of 2.96%. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s payout ratio is currently 94.56%.

Insider Buying and Selling at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on JNJ. UBS Group began coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 target price for the company. Credit Suisse Group boosted their target price on shares of Johnson & Johnson from $168.00 to $170.00 in a research note on Friday, May 5th. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 19th. Guggenheim initiated coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target for the company. Finally, Raymond James lowered their price target on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research report on Wednesday, April 19th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $173.00.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.